Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has provided a trading update for the year ended 30 June 2020.
Reported revenues for the year ended 30 June 2020 are expected to be at least 4% ahead of last year in constant currency terms. A programme of operating cost efficiencies, together with the timing of the planned research and development expenditure over the 3 years to June 2022, are expected to deliver a net profit for the year significantly above market expectations.
The Board looks forward to providing a further update to shareholders for the year to 30 June 2020 in the week commencing 13 July 2020.